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The 2014–2015 Ebola epidemic affected several African countries, claiming more than 11,000 
lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or 
limit future outbreaks. The recombinant vesicular stomatitis virus–vectored Zaire Ebola (rVSV-
ZEBOV) vaccine has shown marked immunogenicity and efficacy in humans but is reactogenic at 
higher doses. To understand its effects, we examined plasma samples from 115 healthy volunteers 
from Geneva who received low-dose (LD) or high-dose (HD) vaccine or placebo. Fifteen plasma 
chemokines/cytokines were assessed at baseline and on days 1, 2 to 3, and 7 after injection. 
Significant increases in monocyte-mediated MCP-1/CCL2, MIP-1β/CCL4, IL-6, TNF-α, IL-1Ra, 
and IL-10 occurred on day 1. A signature explaining 68% of cytokine/chemokine vaccine-
response variability was identified. Its score was higher in HD versus LD vaccinees and was 
associated positively with vaccine viremia and negatively with cytopenia. It was higher in 
vaccinees with injection-site pain, fever, myalgia, chills, and headache; higher scores reflected 
increasing severity. In contrast, HD vaccinees who subsequently developed arthritis had lower day 
1 scores than other HD vaccinees. Vaccine dose did not influence the signature despite its 
influence on specific outcomes. The Geneva-derived signature associated strongly (ρ = 0.97) with 
that of a cohort of 75 vaccinees from a parallel trial in Lambaréné, Gabon. Its score in Geneva HD 
vaccinees with subsequent arthritis was significantly lower than that in Lambaréné HD vaccinees, 
none of whom experienced arthritis. This signature, which reveals monocytes’ critical role in 
rVSV-ZEBOV immunogenicity and safety across doses and continents, should prove useful in 
assessments of other vaccines.
Introduction
A vaccine’s safety is a core element in its development and acceptance, yet there is little 
information on how vaccine-induced responses determine adverse outcomes. Despite recent 
progress in discovery of molecular signatures of vaccine-induced immune responses in 
humans offered by novel, cutting-edge technologies and systems biology approaches, 
biomarkers of vaccine safety and immunogenicity have yet to be identified for most 
vaccines.
There are currently no approved vaccines against Ebola virus disease (EVD). In 2014, an 
EVD outbreak affecting several African countries triggered international collaboration in the 
testing of EVD vaccine candidates (1). The most advanced in its development is the 
replication-competent recombinant vesicular stomatitis virus (rVSV)–based vector vaccine 
expressing the glycoprotein (GP) of the Zaire Ebola virus (rVSV-ZEBOV) (2), which 
conferred a high protection rate in the ring vaccination trial conducted in Guinea (3). The 
phase 1/2 studies were performed in 2014–2015 in the United States (4) and in Africa and 
Europe, with trials in the latter two continents led by a World Health Organization (WHO)–
coordinated consortium [VSV-Ebola Consortium (VEBCON)] (5). In healthy adults, rVSV-
ZEBOV was immunogenic but reactogenic. In phase 1 trials, vaccine doses ranged from 3 × 
105 to 1 × 108 plaque-forming units (pfu), and both reactogenicity and immunogenicity 
proved to be dose-dependent (4–6), although the frequency and intensity of adverse events 
(AEs) were variable. In the Geneva randomized controlled trial (RCT) comparing low-dose 
(LD) (3 × 105 pfu) or high-dose (HD) (1 × 107 or 5 × 107 pfu) vaccine to placebo, 97% of 
vaccinees experienced reactogenicity (6). Characterized by early-onset local and systemic 
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inflammation, it was transient and generally well tolerated (6). In the second week after 
immunization, rVSV-ZEBOV–associated arthritis was identified in 13 of 51 LD and 11 of 
51 HD vaccinees (24%) (6). Although early reactogenicity was similar at other sites, arthritis 
was rarely reported (4, 5). The underlying mechanisms of rVSV-ZEBOV–induced AE 
remain unknown; further investigation is required to determine vaccine safety in vulnerable 
populations such as children, pregnant women, and the immunocompromised and to inform 
the clinical development of other rVSV-based vaccines (7–9). The Innovative Medicine 
Initiative 2 (IMI2) Joint Undertaking–supported VSV-EBOVAC project is examining the 
mechanisms underlying the immunogenicity and safety of rVSV-ZEBOV by using cutting-
edge omics and state-of-the-art technologies (10).
Inflammation results from coordinated vaccine-specific and non-specific biochemical and 
cellular events reflecting cell migration and activation triggered early after infection or 
vaccination. Chemokines attract immune cells such as monocytes, granulocytes, or 
lymphocytes to infected or inflamed tissues (11, 12). Upon activation, these cells locally 
release mediators such as cytokines and chemokines (11), which play a key role in EVD 
(13). Because Ebola virus GP mediates cell tropism in EVD, we postulated that vaccination 
with rVSV-ZEBOV might involve similar target cells.
To study the immunological basis of rVSV-ZEBOV–induced AE and the influence of the 
vaccine dose on these immune responses, we quantified selected chemokines and cytokines 
in the plasma of Geneva vaccinees before and after LD or HD immunization (5, 6). We 
investigated whether a composite pattern of interconnected mediators might be identified. A 
distinct plasma signature emerged, composed of six markers whose up-regulation was 
vaccine dose–dependent and significantly correlated with vaccine-related viremia, cytopenia, 
and AE—including rVSV-ZEBOV–associated arthritis. Extending our analyses to vaccinees 
from Lambaréné, Gabon confirmed the signature’s validity across different genetic 
backgrounds and environmental settings.
Results
The Geneva derivation cohort identifies vaccine-induced, dose-dependent changes in 
specific plasma markers
Plasma samples were collected on days 0, 1, 2 or 3, and 7 in the 115 participants of the 
Geneva RCT (fig. S1) and were subjected to multiplex analysis of 15 chemokines/cytokines 
with documented involvement in responses to Ebola (13–19), VSV (20, 21), or other viral 
vaccines (22, 23). These included monocyte [monocyte chemoattractant protein-1 (MCP-1/
CCL2), macrophage inflammatory protein-1α (MIP-1α/CCL3), and MIP-1β/CCL4]– or 
granulocyte [interleukin-8 (IL-8/CXCL8) and epithelial-derived neutrophil-activating 
peptide 78 (ENA-78/CXCL5)]–attracting chemokines, growth factors [granulocyte-
macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor 
(G-CSF)], proinflammatory [tumor necrosis factor–α (TNF-α) and interferon-γ (IFN-γ)] 
and anti-inflammatory [IL-1 receptor antagonist (IL-1Ra) and IL-10] cytokines, and some T 
cell cytokines (IL-2, IL-4, IL-6, and IL-17). The geometric mean concentrations (GMCs) of 
granulocyte-attracting chemokines, growth factors, T cell cytokines, IL-1β, and MIP-1α/
CCL3 remained unchanged after immunization (table S1). In contrast, a synchronized day 1 
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GMC increase was observed for two monocyte-attracting chemokines (MCP-1/CCL2 and 
MIP-1β/CCL4) and two proinflammatory (IL-6 and TNF-α) and two anti-inflammatory 
(IL-1Ra and IL-10) cytokines (Table 1 and Figs. 1A and 2, A and B). This peak was 
followed by a rapid return to baseline, identifying the ratio of day 1/day 0 GMCs as the 
optimal marker of vaccine responses (table S2). In HD vaccinees, the largest fold increases 
were observed for IL-6 [13.5 (95% CI, 8.3 to 21.9)], IL-1Ra [10.6 (95% CI, 8.4 to 13.4)], 
and IL-10 [7.1 (95% CI, 4.7 to 10.7)], followed by TNF-α [4.0 (95% CI, 2.4 to 6.5)], 
MCP-1/CCL2 [3.4 (95% CI, 3.0 to 3.8)], and MIP-1β/CCL4 [2.3 (95% CI, 2.1 to 2.6)]. 
Although weaker in magnitude, significant changes were also observed in LD vaccinees 
(table S2).
Correlated plasma chemokine/cytokine responses define a specific rVSV-ZEBOV signature
We found that the chemokine and cytokine responses in the plasma of vaccinees correlated 
significantly in a dose-independent manner (table S3, A to C). The strongest associations 
among day 1 GMCs were between MCP-1/CCL2 and MIP-1β/CCL4 (Spearman’s 
correlation coefficient ρ = 0.71, P < 0.001) and between IL-6 and TNF-α (ρ = 0.6, P < 
0.001). Strong correlations were similarly identified for the day 1/day 0 GMC ratios (table 
S4). Cronbach’s α values were 0.89, 0.86, and 0.91 for LD, HD, and all vaccinees, 
respectively, indicating that the variability in vaccine-induced responses is largely based on a 
common trait. Principal components analysis (PCA) identified the contribution of each 
marker to the variability of responses and defined this common trait. A significant 
association was observed in placebo recipients between MCP-1/CCL2 and MIP-1β/CCL4 (ρ 
= 0.66, P < 0.01) (table S4), indicating that this variance was not associated with 
immunization. MIP-1β/CCL4, contributing less to the variability, was thus excluded from 
the equation, without affecting Cronbach’s α (0.88 in all vaccinees). The single principal 
component with an Eigen value greater than 1 (3.38), explaining 68% of the variability of 
the day 1/day 0 chemokine/cytokine ratios, was retained. After normalization and 
standardization, the equation of the signature was defined by “0.266 × MCP-1STD + 0.265 × 
IL-1RaSTD + 0.211 × TNF-αSTD + 0.228 × IL-10STD + 0.242 × IL-6STD,” where each 
marker is expressed by its log10-transformed day 1/day 0 ratio and is standardized.
The score of this equation, henceforth, the Geneva rVSV-ZEBOV signature, was 
significantly influenced by vaccine dose (overall, P < 0.001): It was higher in HD versus LD 
vaccinees [mean, 0.59 (SD, ±0.80) versus −0.61 (SD, ±0.81); P < 0.001] and lowest in 
placebo recipients [mean, −1.12 (SD, ±0.16); P < 0.001 versus HD; fig. S2]. To define the 
influence of the dose on the signature’s equation, we reassessed it separately within the LD 
and HD vaccinees. Similar signatures were obtained (see Supplementary Materials), 
indicating that the equation defining the vaccine signature is dose-independent.
The signature is strongly associated with hematological, virological, and immunological 
outcomes
rVSV-ZEBOV immunization triggers transient, dose-dependent viremia and hematological 
changes (5, 6). We observed strong positive associations between the rVSV-ZEBOV 
signature and peak (ρ = 0.68, P < 0.001), day 1 (ρ = 0.64, P < 0.001), and day 3 (ρ = 0.61, 
P < 0.001) viremia. In contrast, strong negative associations were identified with day 1 
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lymphopenia (ρ = −0.79, P < 0.001) and thrombocytopenia (ρ = −0.55, P < 0.001) and day 
3 thrombocytopenia (ρ = −0.49, P < 0.001) and neutropenia (ρ = −0.42, P < 0.001). Thus, 
higher viral loads were associated with higher signature scores, which, in turn, correlated 
with more pronounced cytopenia. Multivariate analyses indicated that the signature’s 
influences on biological outcomes largely persisted independent of vaccine dose (Table 2).
Given that innate responses are considered to affect subsequent adaptive responses to 
vaccination, we asked whether this day 1 signature correlated with anti–EBOV-GP 
immunoglobulin G (IgG) antibody titers. Significant positive associations were observed at 1 
month (ρ = 0.44, P < 0.001) and 6 months (ρ = 0.45, P < 0.001) after immunization (fig. S3) 
(5, 6). In contrast to biological outcomes, associations with antibody responses essentially 
reflected the influence of the vaccine dose.
Signature scores correlate with the type and severity of vaccine-induced AEs
We next assessed associations between the rVSV-ZEBOV signature and clinical 
characteristics. We found lower scores in females (−0.33 versus 0.04, P = 0.047) and no 
association with age (ρ = 0.12, P = 0.21). As reported, AEs occurred in most (97%) HD 
vaccinees, with dose-dependent incidence and severity (5, 6). Strongly positive associations 
(Table 2) were observed between the score of the chemokine/cytokine signature and 
injection site pain and swelling, fever, myalgia, chills, and even headaches but not early-
onset arthralgia, fatigue, or other AEs (Table 3, table S5, and Fig. 2C). Scores were 
significantly higher in subjects with “any” (at least one) AEs. These AEs correlatedmost 
strongly with changes in the GMCs of the MCP-1/CCL2 and MIP-1β/CCL4 chemokines 
and in IL-1Ra and IL-6 (Table 3). TNF-α elevations were seen only in subjects with myalgia 
or “any AEs.” Thus, local and systemic inflammatory rVSV-ZEBOV–triggered AEs 
presumably reflect the recruitment and activation of specific cells, predominantly 
monocytes, given the role of their chemokines and products.
The standardized grading of the severity of rVSV-ZEBOV–induced AEs (24) identified 63 
vaccinees (62%) with at least one grade ≥2 AE. The scores correlated with the severity of 
subjective fever (P < 0.001), myalgia (P = 0.008), chills (P = 0.003), and any grade ≥2 AEs 
(P = 0.031) (Fig. 2C and table S6).
Although the signature correlated independently with vaccine dose and biological/clinical 
outcomes (Table 2), multivariate analyses indicated that reactogenicity was jointly 
influenced by the dose and the signature (Table 4). As an example, restricting analyses to 
HD vaccinees identified significantly lower IL-10 responses in subjects with early-onset 
arthralgia (table S7), a finding not identified when including all vaccinees (Table 2).
HD vaccinees with subsequent arthritis had lower day 1 signature scores
We previously reported viral arthritis at similar frequencies (20 to 25%) in Geneva HD and 
LD vaccinees, identifying age as a determinant only in LD vaccinees and suggesting that 
distinct mechanisms were at play (6). We thus sought to investigate associations between the 
signature and viral arthritis in each dose group. Similar baseline GMCs were observed in 
subjects with or without subsequent arthritis. In HD vaccinees who later developed arthritis, 
the day 1 score was significantly lower than in their counterparts (Table 5). This reflected 
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significantly lower IL-1Ra, IL-6, TNF-α, MCP-1/CCL2, and MIP-1β/CCL4 responses. In 
contrast, LD vaccinees who later developed arthritis had a higher composite score but 
similar GMCs of cytokines/chemokines as vaccinees without arthritis. Thus, the association 
between rVSV-ZEBOV–induced innate responses and subsequent arthritis is dose-
dependent.
The plasma signature of rVSV-ZEBOV likely originates outside the blood compartment
We next used the dual-color reverse transcriptase multiplex ligation-dependent probe 
amplification (dcRT-MLPA) assay (25) to assess changes in mRNA expression of the 
signature markers in whole-blood RNA samples. Baseline gene expression occasionally 
differed between groups (Table 6), perhaps due to successive rather than simultaneous 
recruitment of HD and LD vaccinees, but was compensated for by using the day 1/day 0 
ratio. Although significant up-regulation of MCP-1/CCL2 and IL-1Ra/IL-1Rn transcripts 
was observed in the blood, the expression of MIP-1β/CCL4, TNF-α, IL-6, and IL-10 
remained unexpectedly unchanged (Table 6, table S8, and fig. S4). Thus, the plasma vaccine 
signature likely reflects vaccine-induced innate responses occurring largely outside of the 
blood compartment.
The rVSV-ZEBOV Geneva and Lambaréné signatures correlate strongly
Vaccine responses may be modulated by genetic and environmental influences. We thus 
asked whether innate responses to rVSV-ZEBOV differ between the Geneva cohort and a 
distinct cohort from an African setting with potential Ebola virus exposure (26, 27). 
Cytokines/chemokines were quantified in cryopreserved plasma samples of 75 subjects 
immunized in Lambaréné (fig. S1). Up-regulated markers included the same chemokines/
cytokines that defined the Geneva signature, peaking on day 1 (Figs. 1B and 2, A and B, and 
table S9). At baseline, higher TNF-α (15-fold), IL-10 (12-fold), and MIP-1β/CCL4 (1.7-
fold) concentrations were observed in Lambaréné than in Geneva, whereas MCP-1/CCL2 
levels were twofold higher in Geneva (table S10). Nevertheless, similar vaccine responses 
were observed in both sites, except for TNF-α and MIP-1β/CCL4, whose higher baseline 
concentrations blunted responses in Lambaréné (Fig. 1B and tables S11 to S13).
To define whether the Geneva signature could predict rVSV-ZEBOV responses elicited 
elsewhere, we applied an independent PCA to the Lambaréné data (see Materials and 
Methods). The main component explained 48.4% of the variability of responses, included 
the same markers, and was translated by a similar signature (0.242 × MCP-1STD + 0.344 × 
IL-1RaSTD + 0.247 × TNF-αSTD + 0.340 × IL-10STD + 0.244 × IL-6STD). Its mean scores 
differed significantly between LD (−1.22 ± 0.78) and HD (0.30 ± 0.80, P < 0.001) vaccinees 
(fig. S5). We next asked whether applying the Geneva signature to the Lambaréné data (fig. 
S6) would generate similar results. Both signatures correlated strongly (ρ = 0.97, P < 0.001; 
Fig. 3) but are not equal. In Lambaréné vaccinees, PCA identified an additional component 
including TNF-α and IL-10, the two cytokines with high baseline concentrations, explaining 
a further 23.5% of the variability of responses. The Lambaréné signature can be derived 
from the Geneva signature and applied to the Lambaréné data (Geneva/Lambaréné 
signature) by the following equation: Lambaréné signature = −0.53 + 1.40 × Geneva/
Lambaréné signature.
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When the Geneva signature was applied to the Lambaréné data, significant positive and 
negative associations were again observed with day 1 viremia (ρ = 0.36, P = 0.002) and 
lymphopenia (ρ = −0.50, P < 0.001) but not thrombocytopenia (table S14). We found 
significant associations with the occurrence (P = 0.001; Table 7 and Fig. 2C) and severity (P 
= 0.001; Fig. 2D and table S14) of any AEs and of injection site pain (P = 0.003; Table 7). 
For other AEs, scores and chemokine/cytokine GMCs were higher in affected subjects but 
did not reach statistical significance. Similarly, responses did not significantly differentiate 
Lambaréné vaccinees with grade 1 or 2 AEs (Fig. 2D and table S14). Although significantly 
fewer Lambaréné HD vaccinees reported fever, chills, and myalgia (tables S15 and S16), 
similar day 1/day 0 cytokine/chemokine responses were observed in both sites (Tables 3 and 
7). Baseline IL-10 concentrations, higher in Lambaréné, were not associated with reduced 
reactogenicity. The signature score of GenevaHDvaccinees with subsequent arthritis [0.16 
(95% CI, 0.12 to 0.44)] was significantly lower than that of Lambaréné HD vaccinees [0.58 
(95% CI, 0.42 to 0.74); P = 0.021; fig. S7], none of whom experienced arthritis.
Discussion
Herein, we report a safety biosignature for rVSV-ZEBOV, identified in the plasma as a 
specific composition of interconnected chemokines/cytokines and validated in two distinct 
cohorts across various vaccine doses and continents. This signature reveals previously 
uncharacterized innate responses to rVSV-ZEBOV and provides insights into their 
contribution to the onset and severity of biological and clinical outcomes.
Among the 15 plasma markers selected for their potential involvement in responses to rVSV-
ZEBOV (13–23), a subset of only six chemokines/cytokines differentiated placebo recipients 
from vaccinees and LD from HD vaccinees. In contrast to the predominantly lymphoid 
markers composing a recently identified H1N1 influenza vaccine signature (28), vaccine 
responses here are monocytic: The two chemokines are monocyte chemoattractants (29), and 
the induced pro- and anti-inflammatory cytokines are monocyte products (30–32). The 
finding that rVSV-ZEBOV preferentially elicits monocyte responses is not unexpected: 
Ebola virus targets monocytes/macrophages (19, 33), and we previously reported their dose-
dependent activation by rVSV-ZEBOV (6). Despite the abundance of blood monocytes, the 
transcript expression of most of these chemokines/cytokines was not increased in blood 
cells. Although blood cells may contribute to the response by releasing proteins such as 
TNF-α and IL-6 from storage vesicles (34, 35), we postulate that this plasma signature is 
generated mostly in extravascular, vaccine-targeted cells and tissues. Responses to rVSV-
ZEBOV, initiated at the site of injection and in the draining lymph nodes, might be 
orchestrated by type I IFNs: In mice, VSV RNA induces high-level production of IFN-α and 
IFN-β (36), known to trigger the six markers (37, 38). In humans, studies initially 
demonstrated that live vaccines such as yellow fever vaccine induce genes regulating virus 
innate sensing and type I IFN production (39, 40). Subsequently, type I IFN was confirmed 
as a pivotal marker of vaccine responses, even in response to inactivated influenza vaccines, 
in both adults (41) and young children (42). Further studies are required to characterize type 
I IFN responses to rVSV-ZEBOV, as well as the relative contribution of rVSV [which 
triggers reactogenicity (21) and transient lymphopenia in mice (43) and induces MCP-1/
CCL2 production by human monocytes (20)] and EBOV-GP [which also triggers immune 
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reactivity (14, 15, 44–50)]. These early innate responses likely play a critical role in the 
large, cross-reactive post-exposure efficacy observed in experimental animal models given 
rVSV-ZEBOV (51, 52). Their potential contribution to the early effectiveness observed in 
the Guinea ring immunization trial (53) is intriguing.
The signature score increased with VSV viremia yet independent of vaccine dose: Its 
positive association, persisting through day 3, suggests a minor and/or insufficient role in the 
control of primary VSV viremia. In contrast, negative dose-independent associations with 
lymphopenia, neutropenia, and thrombocytopenia point to protective effects against virus-
induced cytopenia; whether innate responses reduce cell egress from the blood compartment 
and/or limit virus-mediated cell destruction remains unknown. Although innate immune 
responses set the stage for adaptive vaccine responses (42, 54, 55) and were associated with 
EBOV-GP antibody responses, these were associated with the dose rather than with plasma 
cytokines. It will be of significant interest to define whether (or not) gene expression 
analyses will reveal a direct influence of specific responses [such as type I IFN (36)] on 
antibody titers.
Vaccine reactogenicity has long been thought to reflect innate responses and inflammation. 
Local pain was associated with MCP-1/CCL2, MIP-1β/CCL4, IL-1Ra, and IL-6, likely 
reflecting monocyte recruitment and activation at the injection site. The same markers 
correlated with vaccine-induced fever and “flu-like symptoms,” a finding that again points to 
the preferential activation of monocytes/macrophages by rVSV-ZEBOV (19). IL-1Ra has 
anti-inflammatory properties but is produced as an acute-phase protein also reflecting 
monocyte activation (56). TNF-α was significantly elevated only in myalgia, and early-onset 
arthralgia did not coincide with myalgia but was associated with lower IL-10 responses, 
possibly reflecting the protective role of IL-10 in joint inflammation (57). These influences 
were jointly influenced by the vaccine dose, indicating associations between dose, innate 
responses, and reactogenicity. Comparing the signature of replicating and nonreplicating 
Ebola vaccine candidates (45–50) of rVSV with distinct envelope genes and of rVSV 
vectors with distinct viral properties could shed light on mechanisms underlying their 
relative safety profile and be used in various populations. The acute reactogenicity of rVSV-
ZEBOV was transient and did not prevent its use in the field (53), and vaccine safety was 
subsequently confirmed in thousands of vaccinees (3). Thus, the levels of reactogenicity and 
attendant plasma chemokine and cytokine responses described here may also inform the 
development of standards and standardized templates assessing the risks and benefits of live 
virus vaccines (58).
The pathophysiology leading to the dissemination of rVSV-ZEBOV into the joints and to 
arthritis (5, 6) remained undefined; arthritis after wild-type VSV infection or rVSV 
vaccination with non–EBOV-GP inserts has not been reported (59, 60). Here, we 
demonstrate significantly lower scores and weaker day 1 innate responses in HD vaccinees 
who later developed arthritis. Although higher VSV viremia is associated with higher scores 
(Table 2), days 1 to 3 viral loads were similar in subjects with or without subsequent arthritis 
(6). This suggests that at a high viral inoculum, such as the current dose of 2 × 107 pfu, 
strong early innate responses do not reduce early VSV viremia but may contribute to limit 
the duration of viral replication or viral dissemination in peripheral tissues and subsequent 
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enhanced risks of rVSV-ZEBOV–induced viral arthritis and dermatitis (5, 6). In contrast, in 
LD vaccinees who later developed arthritis, early cytokine/chemokine concentrations were 
similar, and the score was higher compared to that of their LD counterparts. This confirms 
that distinct mechanisms are at play in HD and LD vaccinees, where age is an independent 
factor (6). Further studies are thus needed to define the relative contribution of the 
magnitude and duration of immune responses, the relative role of monocytes in infection 
control versus viral dissemination, and the age-associated joint vulnerability (5, 6); these 
may then help to explain the markedly higher reporting rates of arthritis in Geneva than in 
Lambaréné.
Applying the Geneva signature to an African population at risk of Ebola exposure was key to 
its validation. In Lambaréné, rVSV-ZEBOV up-regulated the same markers, with similar 
responses despite distinct baseline TNF-α, IL-10, and MCP-1/CCL2 levels. The Geneva 
signature correlated highly with that of the independently derived Lambaréné signature.
The frequency of self-reported, vaccine-induced AEs is notably lower in African settings 
(61). We demonstrate here that this lower incidence (5) does not reflect weaker innate 
responses nor higher baseline concentrations of anti-inflammatory cytokines such as IL-10; 
innate responses were similar in European and African volunteers. The fact that the 
signature score of Geneva HD vaccinees with subsequent arthritis is significantly lower than 
that of Lambaréné vaccinees may provide a first explanation for the discrepant reporting of 
arthritis among centers (5). It also emphasizes the importance of assessing vaccine safety in 
the settings where they will be used.
Our study has limitations. Samples were collected in rapidly implemented clinical trials, 
resulting in some missing samples. Further, we preselected markers of potential interest to 
increase the likelihood of detection of vaccine-associated changes. Although this proved 
successful, additional biomarkers are likely to be identified and eventually refine this first 
plasma signature. The measure of 63 markers in an exposed health care worker identified the 
same and additional up-regulated markers (62), some of which were not confirmed in our 
controlled study. Finally, only Geneva participants were randomized; a few of them are 
open-label. Thus, some changes might have been overlooked by distinct baseline values.
Nonetheless, a vaccine signature’s independence from genetic and environmental influences 
could be demonstrated. This signature of the cytokine pattern underlying vaccine 
reactogenicity offers the first lead to understanding the pathophysiology of rVSV-ZEBOV, a 
complex chimeric vaccine with great potential against a deadly disease (53) but with 
reactogenicity at high doses. It strongly suggests the direct influence of innate responses on 
biological and clinical outcomes, including viral dissemination and arthritis. This prompts 
further work toward the use of early signatures to predict subsequent AEs and the 
reassessment of the strategy to use lower doses of rVSV-ZEBOV in subjects with weaker 
immunity, such as young children. It will also be useful in the development of distinct rVSV-
EBOV constructs or of rVSV-based vaccines. The signature’s relevance extends beyond the 
rVSV-ZEBOV vaccine: It highlights the critical contribution of monocyte recruitment and 
activation to both immunogenicity and safety and the possibility that blood transcriptomics 
may fail to identify responses elicited outside the blood compartment.
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Materials and Methods
The VEBCON Consortium
In August 2014, the Public Health Agency of Canada donated 800 vials of the rVSV-
ZEBOV vaccine to WHO, which created VEBCON to initiate dose-ranging phase 1 clinical 
trials. These phase 1 trials were initiated in Germany (NCT02283099), Kenya 
(NCT02296983), Gabon (PACTR2014000089322), and Switzerland [a phase 1/2 RCT; 
NCT02287480] and were supported financially through WHO by grants from the Wellcome 
Trust Foundation, the Bill and Melinda Gates Foundation, and the German Center for 
Infection Research.
The VEBCON Consortium includes the following members: S. T. Agnandji (Centre de 
Recherches Médicales de Lambaréné, Gabon; Institut für Tropenmedizin, 
Universitätsklinikum Tübingen, Germany) and S. Krishna (St George’s University of 
London, U.K.; Institut für Tropenmedizin, Universität Tübingen, Germany; Centre de 
Recherches Médicales de Lambaréné Lambarene, Gabon); P. G. Kremsner and J. S. 
Brosnahan (Institut für Tropenmedizin, Universität Tübingen, Germany; Centre de 
Recherches Médicales de Lambaréné, Gabon); P. Bejon and P. Njuguna (Kenya Medical 
Research Institute, Kilifi, Kenya); M. M. Addo (University Medical Center Hamburg, 
Germany); S. Becker and V. Krähling (Institute of Virology, Marburg, Germany); C.-A. 
Siegrist and A. Huttner (Geneva University Hospitals); and P. Fast (WHO, Geneva, 
Switzerland).
The EBOVAC Consortium
The VSV-EBOVAC Consortium was constituted at the launch of the VSV-EBOVAC IMI2 
project to include its core members. The VSV-EBOVAC Consortium includes the following 
members (in alphabetical order): S. T. Agnandji, R. Ahmed, J. Anderson, F. Auderset, L. 
Borgianni, J. Brosnahan, A. Ciabattini, O. Engler, M. C. Haks, G. Heppner, A. Gerlini, P. G. 
Kremsner, S. Leib, T. Monath, F. Ndungu, P. Njuguna, G. Pozzi, F. Santoro, and C.-A. 
Siegrist.
Study design, population, and key previous outcomes
We performed a prospective derivation and validation cohort study nested within the phase 1 
Geneva (randomized) and Lambaréné (dose-escalation) trials (registration nos. 
NCT02287480 and PACTR201411000919191, respectively), whose biological and clinical 
outcomes have been reported elsewhere (5, 6). All participants with available plasma 
samples (n = 190) were included; these had received an LD [3 × 105 pfu, n = 71 (Geneva, 
51; Lambaréné, 20)] or HD [Geneva, 1 × 107 or 5 × 107 pfu (n = 51); Lambaréné, 3 × 106 or 
2 × 107 pfu (n = 55)] of the same batch of rVSV-ZEBOV or placebo (Geneva, n = 13) (fig. 
S1). Although vaccine reactogenicity, viremia, and ZEBOV-GP–specific IgG enzyme-linked 
immunosorbent assay antibody titers were dose-dependent in Geneva and Lambaréné, 
vaccine-induced arthritis was reported only in Geneva. In that RCT, age emerged as a risk 
factor for rVSV-ZEBOV arthritis in LD but not in HD vaccinees (6).
Huttner et al. Page 10
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Multiplex analyses of chemokines and cytokines
The kinetics of 15 markers were quantified in cryopreserved plasma using a specifically 
designed 15-nucleotide oligomer multiplex (Fluorokine MAP Multiplex Human Cytokine 
Panel, R&D Systems) according to the supplier’s instructions (see Supplementary 
Materials). Briefly, beads conjugated to the analyte-specific capture antibodies, samples, 
standards, and controls were incubated at room temperature for 3 hours. Biotinylated 
detector antibodies and R-phycoerythrin–conjugated streptavidin (SAPE) were subsequently 
added. The mean fluorescence intensity of each analyte was read on the Bio-Plex 200 array 
reader (Bio-Rad Laboratories) using the Luminex xMAP Technology (Luminex 
Corporation). Sample concentrations were calculated using a five-parameter logistic 
regression curve (Bio-Plex Manager 6.0). Interassay variation coefficients were monitored 
using internal controls. These were below 15% for all. Values below each assay’s cutoff 
were arbitrarily valued at 0.01 pg/ml to use a single negative threshold for each marker. 
Alternatively, we used 50% of the minimal detection dose of each specific marker, as 
provided by the manufacturer, to display individual results in Fig. 1. The use of either 
method did not affect the definition of the signature.
Reverse transcriptase multiplex ligation-dependent probe amplification assay
Total RNA from PAXgene blood collection tubes was extracted using the PAXgene Blood 
RNA kit (BD Biosciences) including on-column deoxyribonuclease digestion according to 
the manufacturer’s protocol. RNA was quantified by a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). Gene expression profiles of IL-1RN (IL-1Ra), 
IL-6, TNF-α, IL-10, MCP-1/CCL2, and MIP-1β/CCL4 were determined using dcRT-MLPA, 
as described previously (25, 63). Briefly, for each target-specific sequence, a specific reverse 
transcriptase primer was designed, located immediately downstream of the left- and right-
hand half-probe target sequence. After reverse transcription of 125 ng of RNA using M-
MLV reverse transcriptase (Promega), left- and right-hand half-probes were hybridized to 
the complementary DNA at 60°C overnight. Annealed half-probes were ligated and 
subsequently amplified by polymerase chain reaction (PCR) (33 cycles for 30 s at 95°C, 30 s 
at 58°C, and 60 s at 72°C, followed by 1 cycle for 20 min at 72°C). Primers and probes were 
from Sigma-Aldrich Chemie, and MLPA reagents were from MRC-Holland. PCR 
amplification products were diluted in a 1:10 ratio in Hi-Di formamide containing 400HD 
ROX size standard and analyzed on an Applied Biosystems 3730 capillary sequencer in 
GeneScan mode (BaseClear). Trace data were analyzed using the GeneMapper software 
package 5.0 (Applied Biosystems). Signals below the threshold value for noise cutoff in 
GeneMapper (log2-transformed peak area, ≤7.64) were assigned the threshold value for 
noise cutoff. Subsequently, results from target genes were normalized to the average signal 
of housekeeping gene GAPDH and assigned the threshold value if below 7.64.
Results from target genes were calculated relative to the average signal of reference gene 
GAPDH. After data normalization, signals below the assay cutoff (log2-transformed peak 
area, ≤7.64) were assigned the threshold value for noise cutoff.
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Identification of the Geneva signature
Cronbach’s α was used to assess whether the variation of cytokines/chemokines up-
regulated between days 0 and 1 measured a single trait. Postulating that day 1 changes were 
triggered by immunization, a PCA was conducted in Geneva participants to identify 
components explaining the variability in cytokines/chemokines. The day 1/day 0 ratios of 
the selected cytokines/chemokines were introduced into the model. Ratios were transformed 
(log10 function) to normalize data and were standardized so that the means and the SD 
equaled 0.
The Eigen values for the components were 3.38, 0.70, 0.53, 0.29, and 0.11. The single 
component with the Eigen value greater than 1 was therefore retained. This component 
explained 68% of the variability of the ratios. The equation of this principal component was 
as follows:
0.489 × MCP‐1STD + 0.487 × IL‐1RaSTD + 0.387 × TNF‐ αSTD + 0.419 × IL‐10STD + 0.445 × IL‐6STD
The ratio of cytokines/chemokines introduced in the equation was also standardized. This 
standardization involves the mean and SD of each ratio in the Geneva samples:
IL‐1RaSTD = log 10 IL‐1Ra
day 1/IL‐1Raday 0 − 0.568 /0.572
IL‐6STD = log 10 IL‐6
day 1/IL‐6day 0 − 0.603 /0.937
TNF‐ αSTD = log 10 TNF‐ α
day 1 /TNF‐ αday 0 − 0.334 /0.797
IL‐10STD = log 10 IL‐10
day 1/IL‐10day 0 − 0.489 /0.848
MCP‐1STD = log 10 MCP‐1
day 1/MCP‐1day 0 − 0.295 /0.314
The SD of the signature in participants was 1.84 (and the mean was 0). The coefficient in the 
equation was then divided by 1.84 so that the SD of the signature equals 1. Thus, the final 
equation for the signature was as follows:
Signature = 0.266 × MCP‐1STD + 0.265 × IL‐1RaSTD + 0.211 × TNF‐ αSTD + 0.228 × IL‐10STD + 0.242
× IL‐6STD
The Kaiser-Meyer-Olkin measure of adequacy (64) was assessed to check the adequacy of 
our model. The obtained values were 0.73 for IL-1Ra, 0.83 for IL-6, 0.80 for TNF-α, 0.84 
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for IL-10, and 0.71 for MCP-1; the overall measure of adequacy was 0.77. A measure 
between 0.70 and 0.79 is interpreted as “middling” and between 0.80 and 0.89 as 
“meritorious” (64). We concluded that our model was adequate. The signature was assessed 
in n = 113 participants because two participants had at least one cytokine missing.
Identification of the Lambaréné plasma signature
After the same approach used for the Geneva data, we conducted a PCA with the Lambaréné 
data. The ratio of the five selected cytokines/chemokines was transformed (log10 function) 
and standardized.
The Eigen values for the components were 2.42, 1.18, 0.77, 0.41, and 0.22. The two 
components with an Eigen value greater than 1 were retained. The first component explained 
48% of the variability of ratios of cytokines/chemokines, whereas the second components 
explained 24% of the variability. The equations of these components were as follows:
Component 1 = 0.529 × MCP‐1STD + 0.535 × IL‐1RaSTD + 0.384 × TNF‐ αSTD + 0.376 × IL‐10STD + 0.379
× IL‐6STD
Component 2 = − 0.182 × MCP‐1STD − 0.331 × IL‐1RaSTD + 0.615 × TNF‐ αSTD + 0.538 × IL‐10STD
− 0.437 × IL‐6STD
The ratio of cytokines/chemokines introduced in the equations was also standardized. This 
standardization involved the mean and SD of each ratio in the Lambaréné samples:
IL‐1RaSTD = log 10 IL‐1Ra
day 1/IL‐1Raday 0 − 0.972 /0.467
IL‐6STD = log 10 IL‐6
day 1/IL‐6day 0 − 0.784 /0.983
TNF‐ αSTD = log 10 TNF‐ α
day 1 /TNF‐ αday 0 − 0.131 /0.181
IL‐10STD = log 10 IL‐10
day 1/IL‐10day 0 − 0.571 /0.751
MCP‐1STD = log 10 MCP‐1
day 1/MCP‐1day 0 − 0.498 /0.299
The standardization is not the same as in the Geneva sample because the distribution of the 
ratios of cytokines/chemokines is different in Lambaréné and Geneva.
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Interpreting the first components as the signature, the SD of the signature was 1.56 (and the 
mean was 0). The coefficient in the equation was then divided by 1.56 so that the SD of the 
signature equaled 1. Finally, the equation for the signature was as follows:
Signature = 0.242 × MCP‐1STD + 0.344 × IL‐1RaSTD + 0.247 × TNF‐ αSTD + 0.340 × IL‐10STD + 0.244
× IL‐6STD
The Kaiser-Meyer-Olkin values were 0.60 for IL-1Ra, 0.71 for IL-6, 0.53 for TNF-α, 0.56 
for IL-10, and 0.58 for MCP-1. The overall measure of adequacy was 0.59. A measure 
between 0.50 and 0.59 is interpreted as “miserable,” between 0.60 and 0.69 as “mediocre,” 
and between 0.70 and 0.79 as “middling.” The PCA model in the Lambaréné samples was 
thus less adequate than with the Geneva samples. However, this model identified a similar 
principal component to the signature determined with the Geneva samples and explaining by 
itself 48% of the variability in ratios of cytokines/chemokines. The signature was assessed in 
n = 60 vaccinees; in the remaining 15 vaccinees, at least one cytokine was missing.
Statistical analyses
Chemokines and cytokines were reported by vaccine dose and study day using GMCs 
(log10). GMCs were compared between independent groups using t tests or ANOVA (with 
Scheffe’s correction for multiplicity of tests and post hoc analyses) and over time using 
linear regression models with mixed effects to account for repeated measures. The 
association between the signature and biological outcomes/AEs was assessed using linear 
and logistic regression models with adjustment for the dose. The type I error level was 0.05, 
and all statistical tests were two-sided. Analyses were conducted in R 3.2.2 (R Foundation 
for Statistical Computing, version 2.15.2) and STATA 14.0 IC (StataCorp LP).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank D. Pejovski (WHO Collaborating Center for Vaccine Immunology, Geneva, Switzerland) for contribution 
to cytokine/chemokine data analysis; M. Dhawan (Leiden University Medical Center, Netherlands) for help in 
isolating RNA and dcRT-MLPA; M.-P. Kieny (WHO) for critical contribution to the organization and funding of 
VEBCON trials; O. Lapujade, V. Moorthy, B. Savarese (WHO), S. A. Dubey (Merck), S. Leib, and M. Strasser 
(Federal Office for Civil Protection, Spiez Laboratory, Switzerland) for support of the VSV-EBOVAC project; A. 
Ciabattini (Sclavo Vaccines Association) for graphical support; and the Clinical Research Center of the University 
Hospital and Faculty of Medicine, Geneva.
Funding: The VSV-EBOVAC project is supported by the IMI2 Joint Undertaking (www.imi.europa.eu) within the 
IMI Ebola+program launched in response to the EVD outbreak in Western Africa in 2014 (grant agreement no. 
115842). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and 
innovation program and from the European Federation of Pharmaceutical Industries and Associations. The phase 1 
clinical trials in Geneva and Lambaréné were funded by the Wellcome Trust Foundation through a grant awarded to 
WHO. The Bill and Melinda Gates Foundation contributed to the funding of the Lambaréné trial and the 
coordination of the VEBCON Data Safety Monitoring Board. A grant from the Trafigura Foundation supported the 
work of the Center for Vaccinology of Geneva. The VSV-EBOVAC project is coordinated by the Sclavo Vaccines 
Association (www.sclavo.org), a nonprofit organization devoted to support research and development of human 
vaccines.
Huttner et al. Page 14
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
References
1. Kanapathipillai R, Henao Restrepo AM, Fast P, Wood D, Dye C, Kieny M-P, Moorthy V. Ebola 
vaccine—An urgent international priority. N Engl J Med. 2014; 371:2249–2251. [PubMed: 
25289888] 
2. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk H-D, 
Feldmann H, Stroher U. Properties of replication-competent vesicular stomatitis virus vectors 
expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78:5458–5465. [PubMed: 
15113924] 
3. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, 
Dean NE, Diatta I, Doumbia M, Draguez B, et al. Efficacy and effectiveness of an rVSV-vectored 
vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-
label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017; 389:505–518. [PubMed: 28017403] 
4. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, Moon JE, Ruck RC, Bennett 
JW, Twomey PS, Gutiérrez RL, et al. A recombinant vesicular stomatitis virus ebola vaccine. N 
Engl J Med. 2015; 376:330–341. [PubMed: 25830322] 
5. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer J-A, 
Kraehling V, Kasonta R, Adegnika AA, et al. Phase 1 trials of rVSV ebola vaccine in Africa and 
Europe. N Engl J Med. 2016; 374:1647–1660. [PubMed: 25830326] 
6. Huttner A, Dayer J-A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, 
Goncalves AR, Hooper JW, Kaya G, et al. The effect of dose on the safety and immunogenicity of 
the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. 
Lancet Infect Dis. 2015; 15:1156–1166. [PubMed: 26248510] 
7. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: Re-inventing the bullet. Trends 
Mol Med. 2004; 10:210–216. [PubMed: 15121047] 
8. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy 
against cancer. J Gen Virol. 2012; 93:2529–2545. [PubMed: 23052398] 
9. Buijs PRA, Verhagen JHE, van Eijck CHJ, van den Hoogen BG. Oncolytic viruses: From bench to 
bedside with a focus on safety. Hum Vaccin Immunother. 2015; 11:1573–1584. [PubMed: 
25996182] 
10. Medaglini D, Harandi AM, Ottenhoff THM, Siegrist CA, VSV-EBOVAC Consortium. Ebola 
vaccine R&D: Filling the knowledge gaps. Sci Transl Med. 2015; 7:317ps24.
11. Melchjorsen J. Learning from the messengers: Innate sensing of viruses and cytokine regulation of 
immunity—Clues for treatments and vaccines. Viruses. 2013; 5:470–527. [PubMed: 23435233] 
12. Melchjorsen J, Sorensen LN, Paludan SR. Expression and function of chemokines during viral 
infections: From molecular mechanisms to in vivo function. J Leukoc Biol. 2003; 74:331–343. 
[PubMed: 12949236] 
13. Bixler SL, Goff AJ. The role of cytokines and chemokines in filovirus infection. Viruses. 2015; 
7:5489–5507. [PubMed: 26512687] 
14. Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus 
triggers immune activation and increased vascular permeability. PLOS Pathog. 2014; 
10:e1004509. [PubMed: 25412102] 
15. Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and 
host Toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol. 
2010; 84:27–33. [PubMed: 19846529] 
16. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, 
Capron M, Debré P, McCormick JB, Georges AJ. Human asymptomatic Ebola infection and 
strong inflammatory response. Lancet. 2000; 355:2210–2215. [PubMed: 10881895] 
17. Hill-Batorski L, Halfmann P, Marzi A, Lopes TJS, Neumann G, Feldmann H, Kawaoka Y. Loss of 
interleukin 1 receptor antagonist enhances susceptibility to Ebola virus infection. J Infect Dis. 
2015; 212(Suppl. 2):S329–S335. [PubMed: 26209680] 
18. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF. Ebola 
hemorrhagic fever: Novel biomarker correlates of clinical outcome. J Infect Dis. 2014; 210:558–
566. [PubMed: 24526742] 
Huttner et al. Page 15
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
19. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF. 
Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol. 2013; 
87:3801–3814. [PubMed: 23345511] 
20. Bußfeld D, Nain M, Hofmann P, Gemsa D, Sprenger H. Selective induction of the monocyte-
attracting chemokines MCP-1 and IP-10 in vesicular stomatitis virus-infected human monocytes. J 
Interferon Cytokine Res. 2000; 20:615–621. [PubMed: 10926203] 
21. Athearn K, Sample CJ, Barefoot BE, Williams KL, Ramsburg EA. Acute reactogenicity after 
intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of 
IL-1β. PLOS ONE. 2012; 7:e46516. [PubMed: 23056330] 
22. Hacker UT, Jelinek T, Erhardt S, Eigler A, Hartmann G, Nothdurft HD, Endres S. In vivo synthesis 
of tumor necrosis factor-α in healthy humans after live yellow fever vaccination. J Infect Dis. 
1998; 177:774–778. [PubMed: 9498462] 
23. Zhang J-S, Zhao Q-M, Zuo S-Q, Jia N, Guo X-F. Cytokine and chemokine responses to Japanese 
encephalitis live attenuated vaccine in a human population. Int J Infect Dis. 2012; 16:e285–e288. 
[PubMed: 22325034] 
24. U.S. Food and Drug Administration (FDA). Guidance for Industry: Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA). 
2007. www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
25. Haks MC, Goeman JJ, Magis-Escurra C, Ottenhoff THM. Focused human gene expression 
profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification. 
Vaccine. 2015; 33:5282–5288. [PubMed: 25917681] 
26. Becquart P, Wauquier N, Mahlakõiv T, Nkoghe D, Padilla C, Souris M, Ollomo B, Gonzalez J-P, 
De Lamballerie X, Kazanji M, Leroy EM. High prevalence of both humoral and cellular immunity 
to Zaire ebolavirus among rural populations in Gabon. PLOS ONE. 2010; 5:e9126. [PubMed: 
20161740] 
27. Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. Low seroprevalence of 
IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 
1997. J Infect Dis. 2005; 191:964–968. [PubMed: 15717273] 
28. Sobolev O, Binda E, O’Farrell S, Lorenc A, Pradines J, Huang Y, Duffner J, Schulz R, Cason J, 
Zambon M, Malim MH, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid 
signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016; 
17:204–213. [PubMed: 26726811] 
29. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): 
An overview. J Interferon Cytokine Res. 2009; 29:313–326. [PubMed: 19441883] 
30. Clahsen T, Schaper F. Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells 
by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and 
transmigration. J Leukoc Biol. 2008; 84:1521–1529. [PubMed: 18765478] 
31. Iwamoto S, Iwai S-i, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, Masunaga A, Ogawa Y, 
Oguchi K, Miyazaki A. TNF-α drives human CD14+ monocytes to differentiate into CD70+ 
dendritic cells evoking Th1 and Th17 responses. J Immunol. 2007; 179:1449–1457. [PubMed: 
17641010] 
32. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or 
Mr Hyde? FEBS Lett. 2006; 580:6289–6294. [PubMed: 17097645] 
33. Feldmann H, Bugany H, Mahner F, Klenk H-D, Drenckhahn D, Schnittler H-J. Filovirus-induced 
endothelial leakage triggered by infected monocytes/macrophages. J Virol. 1996; 70:2208–2214. 
[PubMed: 8642644] 
34. Yáñez-Mó M, Siljander PR-M, Andreu Z, Zavec AB, Borrás FE, Buzas EI, Buzas K, Casal E, 
Cappello F, Carvalho J, Colás E, et al. Biological properties of extracellular vesicles and their 
physiological functions. J Extracell Vesicles. 2015; 4
35. Stanley AC, Lacy P. Pathways for cytokine secretion. Physiology. 2010; 25:218–229. [PubMed: 
20699468] 
36. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006; 7:131–137. 
[PubMed: 16424890] 
Huttner et al. Page 16
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
37. Dowell NG, Cooper EA, Tibble J, Voon V, Critchley HD, Cercignani M, Harrison NA. Acute 
changes in striatal microstructure predict the development of interferon-alpha induced fatigue. Biol 
Psychiatry. 2016; 79:320–328. [PubMed: 26169252] 
38. Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. Monocyte chemoattractant protein-1 and 
CCR2 interactions are required for IFN-α/β-induced inflammatory responses and antiviral defense 
in liver. J Immunol. 2005; 174:1549–1556. [PubMed: 15661915] 
39. Luiza-Silva M, Campi-Azevedo AC, Batista MA, Angela Martins M, Sathler Avelar R, da Silveira 
Lemos D, Camacho LAB, de Menezes Martins R, de Lourdes de Sousa Maia M, Guedes Farias 
RH, da Silva Freire M, et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow 
fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis. 
2011; 204:873–883. [PubMed: 21849284] 
40. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, 
Marzolf B, Kennedy K, et al. Systems biology approach predicts immunogenicity of the yellow 
fever vaccine in humans. Nat Immunol. 2009; 10:116–125. [PubMed: 19029902] 
41. Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, Frasca D, Gersten M, 
Mehta AK, Gaujoux R, Li G-M, et al. Systems analysis of immunity to influenza vaccination 
across multiple years and in diverse populations reveals shared molecular signatures. Immunity. 
2015; 43:1186–1198. [PubMed: 26682988] 
42. Nakaya HI, Clutterbuck E, Kazmin D, Wang L, Cortese M, Bosinger SE, Patel NB, Zak DE, 
Aderem A, Dong T, Del Giudice G, et al. Systems biology of immunity to MF59-adjuvanted 
versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci 
USA. 2016; 113:1853–1858. [PubMed: 26755593] 
43. Schattner A, Meshorer A, Wallach D. Involvement of interferon in virus-induced lymphopenia. 
Cell Immunol. 1983; 79:11–25. [PubMed: 6861209] 
44. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, 
Ploquin A, Sitar S, Gordon IJ, et al. Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med. 
2017; 376:928–938. [PubMed: 25426834] 
45. Zhu F-C, Hou L-H, Li J-X, Wu S-P, Liu P, Zhang G-R, Hu Y-M, Meng F-Y, Xu J-J, Tang R, Zhang 
J-L, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based 
Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, 
placebo-controlled, phase 1 trial. Lancet. 2015; 385:2272–2279. [PubMed: 25817373] 
46. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, 
Sitar S, Glover D, Hu Z, Joshi G, et al. Safety and immunogenicity of Ebola virus and Marburg 
virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan 
adults: A phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015; 
385:1545–1554. [PubMed: 25540891] 
47. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, 
Fehling SK, Strecker T, Biedenkopf N, et al. A monovalent chimpanzee adenovirus Ebola vaccine 
boosted with MVA. N Engl J Med. 2016; 374:1635–1646. [PubMed: 25629663] 
48. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, 
Silva-Reyes L, McElrath MJ, De Rosa SC, et al. Safety and immunogenicity of novel adenovirus 
type 26- and modified vaccinia ankara-vectored Ebola vaccines: A randomized clinical trial. 
JAMA. 2016; 315:1610–1623. [PubMed: 27092831] 
49. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, 
Estoppey D, Steiner-Monard V, Lonchampt S, Thierry A-C, et al. Safety and immunogenicity of a 
chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, 
placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016; 16:311–320. 
[PubMed: 26725450] 
50. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, 
Onwuchekwa U, Sztein MB, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US 
adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised 
trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, 
double-blind, placebo-controlled trial. Lancet Infect Dis. 2016; 16:31–42. [PubMed: 26546548] 
Huttner et al. Page 17
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
51. Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, 
Best SM, Feldmann H. VSV-EBOV rapidly protects macaques against infection with the 2014/15 
Ebola virus outbreak strain. Science. 2015; 349:739–742. [PubMed: 26249231] 
52. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H. Vesicular 
stomatitis virus–based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011; 
204(Suppl. 3):S1066–S1074. [PubMed: 21987743] 
53. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, 
Doumbia M, Draguez B, Duraffour S, Enwere G, et al. Efficacy and effectiveness of an rVSV-
vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring 
vaccination cluster-randomised trial. Lancet. 2015; 386:857–866. [PubMed: 26248676] 
54. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B. 
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to 
stimulate polyvalent immunity. J Exp Med. 2006; 203:413–424. [PubMed: 16461338] 
55. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson 
SE, Milton A, Rajam G, Kasturi S, et al. Molecular signatures of antibody responses derived from 
a systems biology study of five human vaccines. Nat Immunol. 2014; 15:195–204. [PubMed: 
24336226] 
56. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-
phase protein. J Clin Invest. 1997; 99:2930–2940. [PubMed: 9185517] 
57. Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J. Collagen-induced arthritis is 
exacerbated in IL-10-deficient mice. Arthritis Res Ther. 2003; 5:R18–R24. [PubMed: 12716449] 
58. Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, 
Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group. Live virus 
vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key 
considerations for a risk/benefit assessment. Vaccine. 2016; 34:6597–6609. [PubMed: 27395563] 
59. Fields BN, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic. 
N Engl J Med. 1967; 277:989–994. [PubMed: 4293856] 
60. Fuchs, JD; Frank, I; Kochar, N; Elizaga, M; Allen, M; Carter, DK; Frahm, N; Kalams, SA; 
Mulligan, M; Sheets, R; Pensiero, M; , et al. paper presented at the 6th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention; Rome. 17 July 2011; 
61. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, Canderan G, Lawson B, 
Kopycinski J, Graham AS, Rowe DK, et al. Immune activation alters cellular and humoral 
responses to yellow fever 17D vaccine. J Clin Invest. 2014; 124:3147–3158. [PubMed: 24911151] 
62. Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, 
Alimonti J, Link CJ Jr, et al. Emergency postexposure vaccination with vesicular stomatitis virus-
vectored Ebola vaccine after needlestick. JAMA. 2015; 313:1249–1255. [PubMed: 25742465] 
63. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, Kaufmann SH, Finos 
L, Magis-Escurra C, Ota MO, Ottenhoff TH, et al. Identification of biomarkers for tuberculosis 
disease using a novel dual-color RT-MLPA assay. Genes Immun. 2012; 13:71–82. [PubMed: 
21956656] 
64. Kaiser HF. An index of factor simplicity. Psychometrika. 1974; 39:31–36.
Huttner et al. Page 18
Sci Transl Med. Author manuscript; available in PMC 2019 February 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 1. Up-regulated plasma markers after rVSV-ZEBOV immunization.
Individual values are expressed in picograms per milliliter for each subject in each dose 
group and at each time point assessed, before and after rVSV-ZEBOV immunization or 
placebo injection in Geneva (A) or Lambaréné (B). The number of samples assessed at each 
time point is given in Table 1 and table S12. Samples with undetectable concentrations were 
arbitrarily given 50% of the specific minimal detection dose, as described in Materials and 
Methods.
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Fig. 2. Plasma chemokines/cytokines and signatures in rVSV-ZEBOV vaccinees from Geneva 
and Lambaréné.
(A) Day 1 GMCs are expressed in picograms per milliliter (IL-6, TNF-α, and IL-10),1 × 
10−2 (MIP-1β/CCL4), 1 × 10−3 (MCP-1/CCL2), or 1 × 10−4 (IL-1Ra) and illustrated for 
Geneva (left) and Lambaréné (right) vaccinees. (B) Vaccine responses, expressed by the day 
1/day 0 ratios, are illustrated for each chemokine and cytokine for which up-regulation was 
observed after immunization in Geneva (left) or Lambaréné (right). (C) The plasma 
signatures are illustrated for Geneva (left) and Lambaréné (right) vaccinees with and without 
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AEs. (D) The plasma signatures are expressed for Geneva (left) and Lambaréné (right) 
vaccinees reporting grade 0 to 3 AEs.
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Fig. 3. Correlation between the Lambaréné signature and the Geneva signature applied to 
Lambaréné vaccinees.
Representation of the signature (in arbitrary units) calculated directly in vaccine recipients 
from Lambaréné (vertical axis) and when applying the Geneva signature to the Lambaréné 
data (horizontal axis).
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Table 1
GMCs of up-regulated markers in Geneva participants.
Analyses included all subjects and the indicated numbers of plasma samples. ANOVA, analysis of variance; 
CI, confidence interval.
Markers Placebo LD (3 × 105 pfu) HD (107 or 5 × 107 pfu) P values for comparison between dose groups 
ANOVA with post hoc Scheffe
Days n GMC (pg/ml)
(95% CI)
n GMC (pg/ml)
(95% CI)
n GMC (pg/ml)
(95% CI)
Global Placebo
versus LD
Placebo
versus HD
LD versus
HD
IL-1Ra 0 13 505.5 (371.1–688.7) 51 581.3 (488.5–691.9) 51 480.3 (410.7–561.6) 0.27 0.76 0.96 0.28
1 13 492.3 (385.4–628.8) 49 1029.3 (797.3–1328.9) 51 5093.9 (3941.5–6583.1) <0.001 0.031 <0.001 <0.001
2 5 352.8 (171.9-724) 28 1307.6 (1079.7–1583.5) 21 1279.2 (960.7–1703.2) <0.001 <0.001 <0.001 0.99
3 8 428.3 (272.3–673.7) 23 784.4 (620.6–991.6) 30 670.3 (558.6–804.3) 0.035 0.035 0.14 0.59
7 13 457.5 (321.8–650.3) 51 689.1 (572.6–829.3) 51 574 (482.3–683.1) 0.099 0.14 0.54 0.37
P = 0.14 P < 0.001 P < 0.001
IL-6 0 13 0.1 (0–0.4) 51 0.4 (0.2–0.8) 51 0.1 (0–0.2) 0.002 0.19 0.89 0.002
1 13 0.1 (0–0.3) 49 0.8 (0.4–1.4) 51 1.2 (0.8–1.9) <0.001 0.003 <0.001 0.50
2 5 0.2 (0–1.1) 28 0.6 (0.3–1.3) 21 0.1 (0–0.3) 0.027 0.67 0.77 0.028
3 8 0 (0–0.1) 23 0.3 (0.1–0.7) 29 0.1 (0–0.2) 0.056 0.077 0.48 0.26
7 13 0.1 (0–0.2) 51 0.3 (0.2–0.6) 51 0.1 (0–0.1) 0.001 0.035 0.90 0.004
P = 0.21 P < 0.001 P < 0.001
TNF-α 0 13 0.2 (0–0.8) 51 0.3 (0.1–0.6) 51 0.3 (0.1–0.5) 0.87 0.88 0.95 0.96
1 13 0.3 (0.1–1) 49 0.4 (0.2–0.7) 51 1 (0.6–1.8) 0.047 0.90 0.18 0.099
2 5 0.3 (0–4) 28 0.6 (0.2–1.6) 21 1.4 (0.6-3) 0.30 0.84 0.43 0.46
3 8 0.1 (0–0.3) 23 0.4 (0.1–1.2) 30 0.6 (0.3–1.5) 0.081 0.21 0.081 0.81
7 13 0.3 (0.1–1.3) 51 0.3 (0.1–0.6) 51 0.5 (0.3–1) 0.46 1 0.74 0.50
P = 0.097 P = 0.11 P < 0.001
IL-10 0 13 0.2 (0.1–0.5) 51 0.1 (0.1–0.1) 51 0.1 (0–0.1) 0.17 0.31 0.17 0.86
1 13 0.2 (0.1–0.4) 49 0.2 (0.1–0.3) 51 0.5 (0.3–0.8) 0.010 0.96 0.11 0.021
2 5 0.2 (0–0.8) 28 0.2 (0.1–0.4) 21 0.2 (0.1–0.4) 0.92 0.95 0.92 0.99
3 8 0.1 (0–0.2) 23 0.1 (0–0.2) 30 0.1 (0–0.1) 0.83 0.94 >0.99 0.84
7 13 0.1 (0–0.4) 51 0.1 (0–0.1) 51 0.1 (0–0.1) 0.52 0.52 0.66 0.93
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Markers Placebo LD (3 × 105 pfu) HD (107 or 5 × 107 pfu) P values for comparison between dose groups 
ANOVA with post hoc Scheffe
Days n GMC (pg/ml)
(95% CI)
n GMC (pg/ml)
(95% CI)
n GMC (pg/ml)
(95% CI)
Global Placebo
versus LD
Placebo
versus HD
LD versus
HD
P = 0.10 P = 0.003 P < 0.001
MCP-1 0 13 180.4 (151–215.6) 51 175.1 (154.1–199) 51 165.9 (153.6–179.3) 0.68 0.97 0.78 0.77
1 13 160.6 (132.9–194) 49 246.1 (209.4–289.1) 51 556 (474.1–652) <0.001 0.053 <0.001 <0.001
2 5 184.2 (138.7–244.6) 27 204 (180.7–230.3) 21 218.1 (185.4–256.5) 0.58 0.83 0.62 0.80
3 8 154.6 (126.2–189.3) 24 197 (172.4–225.1) 30 191.4 (174.5–210) 0.13 0.14 0.20 0.94
7 13 169.4 (142.3–201.8) 51 184.1 (160.5–211.3) 51 176 (161.8–191.5) 0.75 0.81 0.96 0.86
P = 0.42 P < 0.001 P < 0.001
MIP-1β 0 13 23.6 (13.4–41.6) 51 38.8 (33–45.5) 51 32 (26.7–38.4) 0.055 0.070 0.36 0.37
1 13 22.7 (14.1–36.6) 49 52.5 (43.8–62.9) 51 74.1 (61.5–89.1) <0.001 0.001 <0.001 0.048
2 5 19.3 (6.3–59.1) 27 46.7 (37.2–58.7) 21 34.5 (27.6-43) 0.020 0.028 0.21 0.29
3 8 29.3 (17.5-49) 24 38.7 (30.7–48.8) 30 31.6 (24.2–41.1) 0.45 0.61 0.96 0.55
7 13 27.1 (18.2–40.4) 51 34.8 (29.5-41) 51 26.8 (22.1–32.6) 0.13 0.49 >0.99 0.15
P = 0.16 P < 0.001 P < 0.001
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Table 2
Multivariate analyses of the determinants of biological outcomes in Geneva.
Multivariate analyses were conducted to assess the association between the signature and biological outcomes 
adjusting for the vaccine dose. Linear regression models were used. For the factor dose, placebo was the 
reference category (denoted “Ref”): The regression coefficients for LD and HD represent the mean difference 
in the biological outcome compared with placebo, adjusted for the signature. The P value parallel to the 
reference category is the P value for testing the global association between the vaccine dose (all doses) and the 
outcomes. The regression coefficients for the signature represent the mean increase in biological outcomes for 
an increase in signature of one unit, adjusted for the vaccine dose. For some biological outcomes (peak VSV 
and VSV viremia at day 1 and at day 3), a log10 transformation was applied to fulfill the assumptions of a 
linear regression model. n denotes the number of volunteers included in the analyses (that is, those without any 
missing data for the outcomes and the signature).
Outcomes Predictors Estimate (SE) P
Peak VSV
    (log10) (n = 112)
Dose Placebo Ref <0.001
Low 0.04 (0.16) 0.78
High 1.03 (0.19) <0.001
Signature Per unit 0.20 (0.07) 0.003
VSV viremia (log10)
   Day 1 (n = 113) Dose Placebo Ref <0.001
Low 0.01 (0.17) 0.95
High 0.97 (0.21) <0.001
Signature Per unit 0.15 (0.07) 0.035
   Day 3 (n = 112) Dose Placebo Ref <0.001
Low −0.01 (0.17) 0.97
High 0.68 (0.21) 0.001
Signature Per unit 0.24 (0.07) 0.001
Lymphopenia
   Day 1 (n = 113) Dose Placebo Ref <0.001
Low −0.12 (0.06) 0.060
High −0.26 (0.08) <0.001
Signature Per unit −0.19 (0.03) <0.001
   Day 3 (n = 113) Dose Placebo Ref 0.014
Low −0.14 (0.07) 0.043
High −0.01 (0.08) 0.88
Signature Per unit −0.04 (0.03) 0.13
Thrombocytopenia
   Day 1 (n = 113) Dose Placebo Ref 0.55
Low 0.00 (0.02) 0.92
High −0.02 (0.03) 0.53
Signature Per unit −0.04 (0.01) <0.001
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Outcomes Predictors Estimate (SE) P
   Day 3 (n = 113) Dose Placebo Ref 0.022
Low −0.07 (0.02) 0.008
High −0.08 (0.03) 0.013
Signature Per unit −0.03 (0.01) 0.003
Monocytosis
   Day 1 (n = 113) Dose Placebo Ref 0.14
Low 0.23 (0.13) 0.088
High 0.32 (0.16) 0.049
Signature Per unit −0.04 (0.06) 0.48
   Day 3 (n = 113) Dose Placebo Ref 0.048
Low 0.32 (0.14) 0.025
High 0.18 (0.17) 0.30
Signature Per unit −0.04 (0.06) 0.45
Neutropenia
   Day 1 (n = 112) Dose Placebo Ref 0.59
Low 0.10 (0.13) 0.44
High 0.02 (0.15) 0.88
Signature Per unit 0.15 (0.05) 0.006
   Day 3 (n = 111) Dose Placebo Ref <0.001
Low −0.26 (0.07) <0.001
High −0.34 (0.09) <0.001
Signature Per unit −0.05 (0.03) 0.10
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Table 3
Associations between the signature, chemokines/cytokines, and early AEs in Geneva 
participants.
AEs were included if reported within 14 days of VSV-ZEBOV immunization.
Markers* Local pain (n = 53) No local pain (n = 62) Difference/ratio† P‡§
Signature 0.27 (0.00 to 0.54) −0.46 (−0.68 to −0.23) 0.73 (0.37 to 1.08) 0.001
IL-1Ra 6.89 (4.98 to 9.54) 2.21 (1.64 to 2.99) 3.11 (1.99 to 4.87) <0.001
IL-6 7.83 (4.17 to 14.69) 2.31 (1.44 to 3.69) 3.39 (1.53 to 7.51) 0.003
TNF-α 2.61 (1.58 to 4.32) 1.84 (1.17 to 2.91) 1.42 (0.71 to 2.82) 0.32
IL-10 4.73 (2.71 to 8.27) 2.17 (1.38 to 3.41) 2.18 (1.05 to 4.52) 0.036
MCP-1 2.75 (2.27 to 3.34) 1.50 (1.29 to 1.75) 1.83 (1.43 to 2.36) <0.001
MIP-1β 2.03 (1.76 to 2.35) 1.36 (1.18 to 1.56) 1.50 (1.22 to 1.83) 0.001
Objective fever (n = 14) No objective fever (n = 101)
Signature 0.67 (0.25 to 1.09) −0.24 (−0.43 to −0.05) 0.91 (0.41 to 1.40) 0.001
IL-1Ra 10.60 (5.77 to 19.46) 3.19 (2.48 to 4.09) 3.33 (1.64 to 6.74) 0.002
IL-6 14.06 (4.14 to 47.71) 3.36 (2.23 to 5.06) 4.19 (1.04 to 13.88) 0.045
TNF-α 3.21 (1.40 to 7.35) 2.04 (1.41 to 2.95) 1.57 (0.60 to 4.15) 0.34
IL-10 13.29 (4.66 to 37.96) 2.51 (1.74 to 3.62) 5.30 (1.60 to 17.60) 0.009
MCP-1 3.59 (2.56 to 5.04) 1.81 (1.58 to 2.08) 1.98 (1.34 to 2.93) 0.002
MIP-1β 2.10 (1.61 to 2.73) 1.57 (1.40 to 1.76) 1.33 (0.98 to 1.81) 0.066
Subjective fever (n = 49) No subjective fever (n = 66)
Signature 0.31 (−0.02 to 0.63) −0.45 (−0.63 to −0.27) 0.76 (0.38 to 1.13) <0.001
IL-1Ra 7.15 (4.92 to 10.39) 2.27 (1.74 to 2.96) 3.15 (1.98 to 5.01) <0.001
IL-6 8.34 (3.90 to 17.83) 2.33 (1.63 to 3.33) 3.57 (1.52 to 8.40) 0.004
TNF-α 3.28 (1.71 to 6.28) 1.58 (1.14 to 2.19) 2.07 (0.99 to 4.34) 0.053
IL-10 4.73 (2.39 to 9.36) 2.25 (1.57 to 3.21) 2.11 (0.96 to 4.61) 0.062
MCP-1 2.72 (2.23 to 3.32) 1.56 (1.33 to 1.82) 1.75 (1.35 to 2.26) <0.001
MIP-1β 1.95 (1.64 to 2.32) 1.43 (1.26 to 1.62) 1.37 (1.10 to 1.70) 0.048
Myalgia (n = 57) No myalgia (n = 58)
Signature 0.18 (−0.11 to 0.47) −0.43 (−0.63 to −0.24) 0.61 (0.25 to 0.97) 0.001
IL-1Ra 5.29 (3.68 to 7.61) 2.60 (1.93 to 3.51) 2.03 (1.26 to 3.27) 0.004
IL-6 7.19 (3.73 to 13.85) 2.26 (1.50 to 3.39) 3.19 (1.46 to 6.97) 0.004
TNF-α 3.54 (1.95 to 6.45) 1.32 (1.01 to 1.74) 2.68 (1.37 to 5.22) 0.004
IL-10 4.25 (2.33 to 7.75) 2.25 (1.52 to 3.32) 1.89 (0.92 to 3.90) 0.085
MCP-1 2.43 (2.01 to 2.94) 1.61 (1.35 to 1.91) 1.51 (1.17 to 1.96) 0.002
MIP-1β 1.86 (1.59 to 2.17) 1.43 (1.25 to 1.64) 1.30 (1.05 to 1.60) 0.015
Chills (n = 44) No chills (n = 71)
Signature 0.20 (−0.12 to 0.51) −0.32 (−0.54 to −0.11) 0.52 (0.12 to 0.91) 0.011
IL-1Ra 5.92 (3.93 to 8.92) 2.80 (2.11 to 3.72) 2.12 (1.28 to 3.51) 0.004
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Markers* Local pain (n = 53) No local pain (n = 62) Difference/ratio† P‡§
IL-6 6.22 (3.15 to 12.27) 3.09 (1.91 to 5.01) 2.01 (0.86 to 4.69) 0.104
TNF-α 2.65 (1.46 to 4.79) 1.91 (1.27 to 2.88) 1.39 (0.67 to 2.88) 0.38
IL-10 5.18 (2.62 to 10.24) 2.27 (1.53 to 3.36) 2.28 (1.03 to 5.09) 0.043
MCP-1 2.55 (2.03 to 3.19) 1.70 (1.45 to 1.98) 1.50 (1.14 to 1.98) 0.005
MIP-1β 1.87 (1.59 to 2.19) 1.50 (1.31 to 1.72) 1.24 (1.00 to 1.54) 0.047
Arthralgia (n = 17) No arthralgia (n = 98)
Signature −0.10 (−0.44 to 0.24) −0.13 (−0.34 to 0.08) 0.03 (−0.39 to 0.45) 0.89
IL-1Ra 3.96 (2.15 to 7.30) 3.65 (2.80 to 4.76) 1.09 (0.54 to 2.19) 0.81
IL-6 4.30 (1.80 to 10.28) 3.96 (2.54 to 6.17) 1.09 (0.39 to 3.04) 0.87
TNF-α 1.91 (1.15 to 3.16) 2.21 (1.50 to 3.25) 0.86 (0.45 to 1.67) 0.66
IL-10 2.68 (1.66 to 4.33) 3.16 (2.09 to 4.79) 0.85 (0.44 to 1.63) 0.61
MCP-1 2.15 (1.67 to 2.76) 1.94 (1.67 to 2.26) 1.11 (0.82 to 1.50) 0.50
MIP-1β 1.62 (1.35 to 1.94) 1.63 (1.45 to 1.84) 0.99 (0.79 to 1.24) 0.93
Headache (n = 52) No headache (n = 63)
Signature 0.12 (−0.20 to 0.44) −0.33 (−0.53 to −0.14) 0.45 (0.07 to 0.84) 0.021
IL-1Ra 5.56 (3.82 to 8.09) 2.64 (1.97 to 3.55) 2.10 (1.30 to 2.41) 0.003
IL-6 8.36 (4.18 to 16.73) 2.19 (1.48 to 3.24) 3.82 (1.70 to 8.58) 0.002
TNF-α 3.05 (1.54 to 6.02) 1.62 (1.27 to 2.07) 1.88 (0.90 to 3.93) 0.092
IL-10 3.06 (1.67 to 5.64) 3.10 (2.02 to 4.76) 0.99 (0.46 to 2.10) 0.98
MCP-1 2.23 (1.80 to 2.77) 1.78 (1.51 to 2.10) 1.25 (0.95 to 1.65) 0.11
MIP-1β 1.71 (1.43 to 2.04) 1.57 (1.38 to 1.78) 1.09 (0.87 to 1.36) 0.46
Fatigue (n = 69) No fatigue (n = 46)
Signature −0.07 (−0.34 to 0.19) −0.21 (−0.45 to 0.03) 0.14 (−0.22 to 0.50) 0.45
IL-1Ra 3.88 (2.81 to 5.37) 3.43 (2.38 to 4.96) 1.13 (0.69 to 1.86) 0.62
IL-6 5.27 (3.00 to 9.26) 2.65 (1.60 to 4.38) 1.99 (0.93 to 4.27) 0.078
TNF-α 2.41 (1.43 to 4.08) 1.82 (1.35 to 2.46) 1.32 (0.72 to 2.45) 0.37
IL-10 2.81 (1.71 to 4.61) 3.55 (2.14 to 5.90) 0.79 (0.39 to 1.62) 0.52
MCP-1 2.04 (1.70 to 2.45) 1.87 (1.54 to 2.28) 1.09 (0.83 to 1.43) 0.53
MIP-1β 1.70 (1.47 to 1.96) 1.53 (1.31 to 1.78) 1.11 (0.90 to 1.38) 0.33
Any AEs (n = 106) No AEs (n = 9)
Signature −0.08 (−0.27 to 0.12) −0.70 (−1.07 to −0.34) 0.62 (0.17 to 1.08) 0.011
IL-1Ra 3.93 (3.04 to 5.08) 1.83 (1.11 to 2.99) 2.15 (1.17 to 3.97) 0.018
IL-6 4.46 (2.92 to 6.80) 1.17 (0.60 to 2.26) 3.83 (1.64 to 8.94) 0.004
TNF-α 2.32 (1.61 to 3.33) 0.94 (0.69 to 1.28) 2.47 (1.51 to 4.04) 0.001
IL-10 3.27 (2.22 to 4.80) 1.59 (0.86 to 2.95) 2.05 (0.93 to 4.50) 0.071
MCP-1 2.03 (1.76 to 2.34) 1.42 (0.99 to 2.04) 1.43 (0.92 to 2.22) 0.098
MIP-1β 1.67 (1.49 to 1.87) 1.25 (1.00 to 1.57) 1.33 (1.00 to 1.76) 0.048
*
Mean values (95% CI).
†
Mean difference (signature) and mean ratios (chemokines/cytokines) between participants with and without specific AEs.
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‡Signature: t tests were conducted to compare the mean signature in participants with or without specific AEs.
§Chemokines/cytokines: P value for the comparison of the day 1/day 0 ratio of plasma markers between participants with and without each AE. t 
tests were conducted on log10-transformed data.
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Table 4
Multivariate analyses of the determinants of clinical outcomes in Geneva vaccinees (n = 
102)
Multivariate analyses were conducted to assess the association between the signature and AEs adjusting for 
the vaccine dose. Logistic regression models were used. The reported adjusted odds ratios (ORs) capture the 
increase in risk of an AE compared with the reference category (denoted “Ref”).
AEs (outcome) Predictors Adjusted OR (95% CI) P
Pain Dose Low Ref
High 13.98 (4.01–48.72) <0.001
Signature <0 Ref
≥0 1.05 (0.30–3.64) 0.94
Objective fever Dose Low Ref
High 8.42 (0.84–84.42) 0.070
Signature <0 Ref
≥0 3.00 (0.51–17.54) 0.22
Subjective fever Dose Low Ref
High 3.36 (1.16–9.68) 0.025
Signature <0 Ref
≥0 1.97 (0.69–5.66) 0.21
Myalgia Dose Low Ref
High 2.36 (0.83–6.66) 0.11
Signature <0 Ref
≥0 1.60 (0.56–4.54) 0.38
Arthralgia Dose Low Ref
High 0.94 (0.23–3.88) 0.94
Signature <0 Ref
≥0 1.62 (0.39–6.64) 0.51
Chills Dose Low Ref
High 3.84 (1.25–11.74) 0.018
Signature <0 Ref
≥0 0.73 (0.24–2.20) 0.57
Headache Dose Low Ref
High 1.87 (0.67–5.28) 0.23
Signature <0 Ref
≥0 1.78 (0.63–5.00) 0.28
Fatigue Dose Low Ref
High 1.11 (0.37–3.29) 0.85
Signature <0 Ref
≥0 0.55 (0.18–1.61) 0.27
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Table 5
Innate responses (day 1/day 0 ratios of geometric means) and association with rVSV-
ZEBOV arthritis.
Analyses included all vaccinees (n = 102).
HD group Arthritis (n = 11) No arthritis (n = 40) P* Difference of ratios (95% CI)†
Signature −0.16 (−0.12 to 0.44) 0.70 (0.45 to 0.96) 0.009 −0.54 (−0.94 to −0.14)
IL-1Ra 6.23 (4.27 to 9.10) 12.28 (9.15 to 16.47) 0.011 0.51 (0.31 to 0.84)
IL-6 4.37 (1.44 to 13.25) 18.37 (9.14 to 36.89) 0.045 0.24 (0.06 to 0.97)
TNF-α 2.01 (1.16 to 3.47) 4.80 (2.73 to 8.45) 0.037 0.42 (0.19 to 0.95)
MCP-1 2.59 (2.20 to 3.06) 3.59 (2.99 to 4.33) 0.014 0.72 (0.56 to 0.93)
MIP-1β 1.91 (1.70 to 2.18) 2.44 (2.12 to 2.80) 0.017 0.78 (0.64 to 0.96)
IL-10 6.03 (2.09 to 17.44) 7.40 (4.27 to 12.82) 0.74 0.82 (0.21 to 2.98)
LD group Arthritis (n = 13) No arthritis (n = 38) P value* Difference of ratios (95% CI)†
Signature −0.19 (−0.62 to 0.25) −0.75 (−1.00 to −0.50) 0.042 0.56 (0.02 to 1.10)
IL-1Ra 2.43 (1.47 to 4.03) 1.58 (1.17 to 2.14) 0.18 1.54 (0.81 to 2.946)
IL-6 4.25 (1.35 to 13.39) 1.37 (0.93 to 2.02) 0.099 3.11 (0.78 to 12.38)
TNF-α 2.68 (0.86 to 8.34) 1.03 (0.56 to 1.89) 0.18 2.60 (0.62 to 10.87)
MCP-1 1.67 (1.37 to 2.04) 1.33 (1.11 to 1.59) 0.12 1.26 (0.94 to 1.68)
MIP-1β 1.56 (1.23 to 1.97) 1.23 (1.02 to 1.48) 0.14 1.27 (0.92 to 1.75)
IL-10 5.28 (1.78 to 15.63) 1.36 (0.75 to 2.49) 0.053 3.87 (0.98 to 15.34)
*
t test on the signature and on log10-transformed ratios for cytokines/chemokines.
†
Mean difference in signature or ratios of the geometric mean ratio (cytokines/chemokines) in vaccinees with or without arthritis.
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Table 6
Relative gene expression levels (log2) of markers comprising the plasma signature in 
rVSV-ZEBOV vaccinees or placebo recipients of Geneva.
Analyses included all vaccinees (n = 102) and placebo controls (n = 13).
Placebo LD (3 × 105 pfu) HD (107 or 5 × 107 pfu) P values for comparison between dose 
groups ANOVA with post hoc Scheffe
Days n GMC* (95% CI) n GMC* (95% CI) n GMC* (95% CI) P versus LD P versus HD LD versus HD
IL-1RN (IL-1Rα) 0 13 13.59 (13.08–14.09) 51 14.17 (13.99–14.36) 51 12.39 (12.02–12.75) 0.18 0.001 <0.001
1 13 13.93 (13.39–14.48) 51 15.04 (14.71–15.37) 51 15.81 (15.64–15.98) 0.001 <0.001 <0.001
IL-6 0 13 8.61 (7.74–9.48) 51 8.33 (8.14–8.51) 51 7.95 (7.83–8.07) 0.43 0.012 0.028
1 13 8.06 (7.68–8.45) 51 7.97 (7.76–8.17) 51 7.73 (7.64–7.81) 0.87 0.17 0.11
TNF-α 0 13 11.20 (11.08–11.31) 51 11.16 (11.08–11.25) 51 11.06 (10.97–11.15) 0.93 0.31 0.19
1 13 11.22 (11.02–11.42) 51 11.26 (11.18–11.34) 51 11.49 (11.37–11.60) 0.95 0.056 0.006
IL-10 0 13 7.83 (7.61–8.04) 51 7.76 (7.67–7.85) 51 7.89 (7.66–8.15) 0.95 0.96 0.62
1 13 7.66 (7.61–7.71) 51 7.74 (7.64–7.84) 51 7.94 (7.72–8.16) 0.91 0.30 0.22
MCP-1 0 13 7.81 (7.59–8.03) 51 7.91 (7.78–8.04) 51 7.65 (7.63–7.66) 0.64 0.31 0.001
1 13 7.78 (7.64–7.92) 51 10.52 (10.13–10.91) 51 11.66 (11.44–11.89) <0.001 <0.001 <0.001
MIP-1β 0 13 10.97 (10.67–11.27) 51 10.65 (10.44–10.87) 51 10.99 (10.89–11.09) 0.21 >0.99 0.017
1 13 10.95 (10.62–11.28) 51 10.88 (10.76–11.01) 51 11.04 (10.92–11.16) 0.90 0.79 0.20
*We report the GMC of log2-transformed relative expression levels in whole-blood samples normalized against glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).
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Table 7
Associations between the signature, chemokines/cytokines and main vaccine-related AEs 
in Lambaréné vaccinees.
AEs were included if reported within 14 days of VSV-ZEBOV immunization. “Missing” indicates the number 
of subjects without available day 0 or day 1 plasma samples, that is, not included.
Markers Local pain (n = 42) No local pain (n = 33) Difference/ratio* P†‡
Missing 10 5
Signature 0.65 (0.44 to 0.86) 0.13 (−0.12 to 0.38) 0.52 (0.18 to 0.85) 0.003
IL-1Ra 11.53 (8.36 to 15.90) 7.83 (5.14 to 11.94) 1.47 (0.86 to 1.06) 0.16
IL-6 10.73 (4.66 to 24.71) 3.71 (1.74 to 7.91) 2.90 (0.92 to 9.16) 0.070
TNF-α 1.43 (1.29 to 1.59) 1.29 (1.08 to 1.53) 1.12 (0.90 to 1.38) 0.30
IL-10 6.35 (3.63 to 11.12) 2.34 (1.25 to 4.35) 2.72 (1.16 to 6.39) 0.022
MCP-1 4.14 (3.39 to 5.06) 2.47 (1.92 to 3.17) 1.68 (1.21 to 2.32) 0.003
MIP-1β 1.66 (1.42 to 1.94) 1.22 (1.01 to 1.48) 1.36 (1.05 to 1.75) 0.020
Markers Objective fever (n = 7) No objective fever (n = 68) Difference/ratio* P†‡
Missing 1 14
Signature 0.73 (0.20 to 1.27) 0.33 (0.15 to 0.52) 0.40 (−0.30 to 1.10) 0.22
IL-1Ra 13.99 (6.87 to 28.46) 8.97 (6.70 to 12.01) 1.56 (0.61 to 3.96) 0.30
IL-6 16.03 (1.56 to 165.07) 5.47 (3.05 to 9.79) 2.93 (0.14 to 61.77) 0.42
TNF-α 1.30 (1.02 to 1.64) 1.36 (0.21 to 1.53) 0.95 (0.70 to 1.30) 0.73
IL-10 7.12 (3.15 to 16.11) 3.47 (2.15 to 5.58) 2.05 (0.69 to 6.12) 0.17
MCP-1 4.09 (3.15 to 5.33) 3.05 (2.53 to 3.69) 1.34 (0.93 to 1.93) 0.10
MIP-1β 1.39 (1.02 to 1.89) 1.41 (1.22 to 1.63) 0.99 (0.66 to 1.48) 0.93
Markers Subjective fever (n = 18) No subjective fever (n = 67) Difference/ratio* P†‡
Missing 1 14
Signature 0.54 (0.24 to 0.85) 0.31 (0.09 to 0.52) 0.23 (−0.15 to 0.62) 0.22
IL-1Ra 11.73 (7.26 to 18.95) 8.59 (6.18 to 11.93) 1.37 (0.75 to 2.50) 0.30
IL-6 7.43 (2.74 to 20.14) 5.62 (2.79 to 11.33) 1.32 (0.37 to 4.68) 0.66
TNF-α 1.44 (1.21 to 1.72) 1.32 (1.16 to 1.50) 1.09 (0.87 to 1.37) 0.44
IL-10 6.66 (2.93 to 15.12) 2.96 81.78 to 4.92) 2.25 (0.82 to 6.15) 0.11
MCP-1 3.39 (2.55 to 4.51) 3.05 (2.46 to 3.79) 1.11 (0.77 to 1.61) 0.57
MIP-1β 1.54 (1.27 to 1.87) 1.36 (1.15 to 1.61) 1.13 (0.87 to 1.47) 0.36
Markers Myalgia (n = 12) No myalgia (n = 63) Difference/ratio* P†‡
Missing 0 15
Signature 0.55 (0.26 to 0.84) 0.33 (0.12 to 0.54) 0.22 (−0.16 to 0.59) 0.24
IL-1Ra 11.17 (6.65 to 18.77) 9.98 (6.55 to 12.32) 1.24 (0.65 to 2.37) 0.49
IL-6 4.58 (2.41 to 8.73) 6.53 (3.25 to 13.14) 0.70 (0.26 to 1.87) 0.47
TNF-α 1.38 (1.18 to 1.61) 1.35 (1.19 to 1.53) 1.03 (0.83 to 1.27) 0.81
IL-10 6.95 (2.65 to 18.25) 3.19 (1.96 to 5.18) 2.18 (0.68 to 6.98) 0.18
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Markers Local pain (n = 42) No local pain (n = 33) Difference/ratio* P†‡
MCP-1 4.08 (2.99 to 5.56) 2.95 (2.41 to 3.60) 1.38 80.93 to 2.05) 0.10
MIP-1β 1.46 (1.15 to 1.84) 1.40 (1.20 to 1.63) 1.04 (0.78 to 1.40) 0.77
Markers Chills (n = 4) No chills (n = 71) Difference/ratio* P†‡
Missing 0 15
Signature 0.86 (0.27 to 1.46) 0.34 (0.16 to 0.52) 0.52 (−0.40 to 1.45) 0.18
IL-1Ra 23.42 (10.15 to 54.01) 8.79 (6.65 to 11.62) 2.67 (0.73 to 9.66) 0.10
IL-6 8.72 (0.91 to 83.93) 5.93 (3.27 to 10.77) 1.47 (0.04 to 50.97) 0.77
TNF-α 1.68 (1.12 to 2.50) 1.33 (1.19 to 1.49) 1.26 (0.67 to 2.35) 0.35
IL-10 7.69 (2.88 to 20.58) 3.54 (2.23 to 5.61) 2.17 (0.50 to 9.55) 0.23
MCP-1 4.81 (2.93 to 7.90) 3.05 (2.54 to 3.66) 1.58 (0.74 to 3.37) 0.17
MIP-1β 1.27 (0.79 to 2.03) 1.42 (1.24 to 1.63) 0.89 (0.43 to 1.86) 0.68
Markers Any AEs (n = 45) No AEs (n = 30) Difference/ratio* P†‡
Missing 5 10
Signature 0.59 (0.40 to 0.78) −0.06 (−0.35 to 0.24) 0.65 (0.28 to 1.01) 0.001
IL-1Ra 11.82 (8.94 to 15.62) 5.91 (3.40 to 10.29) 2.00 (1.05 to 3.82) 0.037
IL-6 8.18 (4.24 to 15.79) 3.37 (1.14 to 9.95) 2.43 (0.65 to 9.03) 0.18
TNF-α 1.40 (1.28 to 1.54) 1.26 (0.98 to 1.64) 1.11 (0.83 to 1.48) 0.47
IL-10 6.15 (3.87 to 9.78) 1.37 (0.63 to 2.96) 4.49 (1.76 to 11.45) 0.003
MCP-1 3.83 (3.19 to 4.60) 2.12 (1.55 to 2.89) 1.81 (1.24 to 2.63) 0.003
MIP-1β 1.56 (1.36 to 1.79) 1.16 (0.88 to 1.51) 1.35 (0.98 to 1.85) 0.064
*We report the mean difference (signature) and mean ratios (chemokines/cytokines) between participants with and without specific AEs.
†Signature: t tests were conducted to compare the signature in participants with or without specific AEs.
‡Chemokines/cytokines: P value for the comparison of the day 1/day 0 ratio of plasma markers between participants with and without each AE. t 
tests were conducted on log10-transformed data.
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